Lixisenatide In the ELIXA (Evaluation of Lixisenatide in Acute Coronary Syndrome) study, T2D patients with a recent coronary artery event were randomly assigned (1:1) to a lixisenatide (1020 g) group or placebo group (Pfeffer et al., 2015)
Resources like the retatrutide dosing guide and the 20mg dosing guide cover various scenarios in detail
Clinical anecdotes that patients treated with semaglutide, a glucagon-like peptide-1 receptor (GLP1R) agonist approved for treating type 2 diabetes (T2D) in 2017 and for weight management in 2021 reported reduced desire to drink and smoke have attracted attention regarding its potential to treat addiction [12]
They dont fit the typical prescribing criteria for GLP-1snamely, having diabetes or being obese
Duration matters significantly: short-term prednisone courses (less than 2-4 weeks) cause minimal metabolic disruption to your GLP-1 progress, whereas long-term prednisone therapy (months or years) for conditions like lupus, rheumatoid arthritis, or chronic obstructive pulmonary disease creates sustained metabolic challenges
A Final Word on GLP-1 and Pregnancy GLP-1 drugs have become a big step forward in managing weight and metabolism, but pregnancy changes the situation